Editorial: Pharmacovigilance and drug repositioning research using pharmacoepidemiology

Yoshihiro Noguchi; Miao Yan; Satoshi Yokoyama; Elisabetta Poluzzi

doi:10.3389/fphar.2023.1225909

Editorial: Pharmacovigilance and drug repositioning research using pharmacoepidemiology

Front Pharmacol. 2023 Jun 26:14:1225909. doi: 10.3389/fphar.2023.1225909. eCollection 2023.

Authors

Yoshihiro Noguchi¹, Miao Yan^{2

3

4}, Satoshi Yokoyama⁵, Elisabetta Poluzzi⁶

Affiliations

¹ Laboratory of Clinical Pharmacy, Gifu Pharmaceutical University, Gifu, Japan.
² Department of Pharmacy, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
³ Toxicology Counseling Center of Hunan Province, Changsha, Hunan, China.
⁴ International Research Center for Precision Medicine, Transformative Technology and Software Services, Changsha, Hunan, China.
⁵ Division of Drug Informatics, School of Pharmacy, Kindai University, Higashi-osaka, Japan.
⁶ Pharmacology Unit, Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum-University of Bologna, Bologna, Italy.

No abstract available

Keywords: adverse events; drug repositioning; drug-drug interactions (DDI); pharmacoepidemiology; pharmacovigilance; synergy pharmaceutical science.

Publication types

Editorial

Grants and funding

YN is supported by JSPS KAKENHI Grant Numbers JP22K12890. MY is supported by National Natural Science Foundation of China (Grant No. 81803830). SY is supported by JSPS KAKENHI Grant Number JP19K16461.